Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Basic advances in serotonin pharmacology.

¹Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285.

The Journal of Clinical Psychiatry

|October 1, 1992

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Persistence of long-lasting serotonin depletion by p-chloroamphetamine in rat brain after 6-hydroxydopamine lesioning of dopamine neurons.

Biochemical pharmacology·1995

Same author

Assessing equivalence of inhaled drugs.

Respiratory medicine·1995

Same author

Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement--patterns of failure.

Radiology·1995

Same author

The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis.

Clinical otolaryngology and allied sciences·1995

Same author

Systemic effects of glucocorticoids--a response.

British journal of clinical pharmacology·1995

Same author

Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?

Chest·1995

Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026

Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026

Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026

Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026

Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026

Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026

See all related articles

Advances in serotonin pharmacology, including selective serotonin reuptake inhibitors and receptor subtype characterization, offer new therapeutic strategies for psychiatric disorders and enhance understanding of brain serotonin systems.

Area of Science:

Neuroscience
Psychopharmacology
Molecular Pharmacology

Background:

Serotonin (5-HT) neurotransmission is crucial in psychiatric disorders.
Selective serotonin reuptake inhibitors (SSRIs) highlight the role of serotonin in depression.
Understanding serotonin receptor subtypes is key to developing targeted therapies.

Purpose of the Study:

To review recent advances in serotonin pharmacology.
To discuss the implications of these advances for psychiatry.
To explore the development of novel therapeutic agents and diagnostic tools.

Main Methods:

Characterization of multiple serotonin receptor subtypes.
Development of highly selective agonists and antagonists.
Utilizing pharmacologic probes to assess brain serotonin neuron functionality.

Related Experiment Videos

Main Results:

Selective serotonin uptake inhibitors confirm the relevance of serotonin to depression.
Identification of multiple serotonin receptor subtypes allows for targeted drug development.
Improved pharmacologic specificity enables better assessment of serotonin system function.

Conclusions:

Advances in serotonin pharmacology are expanding our understanding of its role in brain health and disease.
New therapeutic agents targeting serotonin pathways are emerging.
Enhanced tools for imaging and assessing serotonin systems will improve psychiatric treatment.